Nancy E. Davidson
#103,964
Most Influential Person Now
Nancy E. Davidson's AcademicInfluence.com Rankings
Nancy E. Davidsonphilosophy Degrees
Philosophy
#4165
World Rank
#6576
Historical Rank
Logic
#1687
World Rank
#2502
Historical Rank

Nancy E. Davidsonbiology Degrees
Biology
#5360
World Rank
#7818
Historical Rank
Immunology
#248
World Rank
#258
Historical Rank

Download Badge
Philosophy Biology
Nancy E. Davidson's Degrees
- Doctorate Medicine Harvard University
Why Is Nancy E. Davidson Influential?
(Suggest an Edit or Addition)Nancy E. Davidson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. (2005) (5306)
- Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
- Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. (2007) (2993)
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
- Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. (1993) (1992)
- Estrogen carcinogenesis in breast cancer. (2006) (1729)
- Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. (1995) (1490)
- Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. (2003) (1462)
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. (2010) (1260)
- Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon (1994) (1253)
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer (2003) (1091)
- Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. (2005) (1044)
- Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. (2014) (1004)
- A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. (2004) (880)
- E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. (1995) (876)
- Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. (2014) (741)
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. (2015) (722)
- Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. (2011) (685)
- Weekly paclitaxel in the adjuvant treatment of breast cancer. (2008) (673)
- Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. (2014) (671)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
- Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. (2008) (611)
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
- American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. (2006) (527)
- American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. (2010) (524)
- Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. (1994) (516)
- Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. (2013) (513)
- Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. (1993) (511)
- Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. (2008) (507)
- A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast (2013) (476)
- Adjuvant ovarian suppression in premenopausal breast cancer. (2015) (467)
- Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. (1988) (459)
- Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. (2020) (457)
- Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. (1991) (448)
- Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. (1999) (437)
- Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. (2016) (435)
- Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. (2002) (392)
- Exercise manages fatigue during breast cancer treatment: A randomized controlled trial (2005) (378)
- Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells (2001) (359)
- Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. (2001) (356)
- Anticancer activities of novel chalcone and bis-chalcone derivatives. (2006) (349)
- Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR (2001) (348)
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer (2018) (348)
- Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers (2014) (344)
- HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. (2006) (344)
- Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. (1995) (328)
- Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. (2008) (326)
- Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. (2014) (324)
- Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. (2000) (306)
- Sulforaphane induces cell type–specific apoptosis in human breast cancer cell lines (2007) (305)
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. (2019) (294)
- Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. (2007) (293)
- Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. (1996) (290)
- Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. (2013) (283)
- Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. (1996) (280)
- Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. (2003) (279)
- Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. (1987) (278)
- American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. (1999) (258)
- Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. (1987) (256)
- Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. (2001) (253)
- Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. (2011) (251)
- Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. (2000) (240)
- Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. (2004) (238)
- Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer (2007) (232)
- Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. (1994) (230)
- Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. (2008) (230)
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. (2016) (228)
- Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2014) (225)
- Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. (2015) (223)
- HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. (2010) (222)
- DNA methylation in breast cancer. (2001) (221)
- Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). (2005) (215)
- Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. (2009) (214)
- The biology of breast carcinoma (2003) (210)
- MCF-7 cells--changing the course of breast cancer research and care for 45 years. (2015) (199)
- Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer (2012) (197)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Mapping of ER Gene CpG Island Methylation by Methylation-specific Polymerase Chain Reaction (1998) (197)
- Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. (2006) (196)
- The Loss of Estrogen and Progesterone Receptor Gene Expression in Human Breast Cancer (2004) (193)
- Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles (2012) (190)
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. (2018) (184)
- Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. (2008) (179)
- Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. (1994) (179)
- Modulation of aflatoxin metabolism, aflatoxin-N7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. (1986) (176)
- Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. (2005) (176)
- Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. (2009) (175)
- The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. (1996) (169)
- Autocrine and paracrine growth regulation of human breast cancer. (1986) (169)
- Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy (2013) (166)
- Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. (2005) (165)
- High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. (1991) (164)
- Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. (2009) (164)
- Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients (2015) (163)
- A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine (2003) (162)
- Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells (2008) (158)
- Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases (2008) (157)
- Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. (2015) (155)
- Role of Estrogen Receptor Gene Demethylation and DNA Methyltransferase·DNA Adduct Formation in 5-Aza-2′deoxycytidine-induced Cytotoxicity In Human Breast Cancer Cells* (1997) (155)
- Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation (2007) (149)
- Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. (2014) (141)
- Estrogen Replacement Therapy in Breast Cancer Survivors: A Time for Change (1994) (140)
- Mapping of ER gene CpG island methylation-specific polymerase chain reaction. (1998) (140)
- Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. (1998) (136)
- A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100 (2006) (135)
- Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. (2007) (135)
- Increased Protein Stability Causes DNA Methyltransferase 1 Dysregulation in Breast Cancer* (2005) (131)
- NCCN Practice Guidelines for Breast Cancer. (2000) (129)
- Transforming Cancer Prevention through Precision Medicine and Immune-oncology (2016) (128)
- Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
- Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. (1997) (125)
- Epigenetics in breast cancer: what's new? (2011) (125)
- Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells (2010) (125)
- Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases (2017) (121)
- Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid (2006) (118)
- Spermine Oxidase SMO(PAOh1), Not N1-Acetylpolyamine Oxidase PAO, Is the Primary Source of Cytotoxic H2O2 in Polyamine Analogue-treated Human Breast Cancer Cell Lines* (2005) (115)
- Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. (1992) (113)
- Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells (2012) (113)
- Inhibition of Histone Lysine-specific Demethylase 1 Elicits Breast Tumor Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade (2018) (112)
- Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. (2014) (112)
- Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. (2013) (111)
- The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway (2011) (110)
- Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. (1995) (109)
- Fenugreek: A naturally occurring edible spice as an anticancer agent (2009) (106)
- Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models (2017) (101)
- Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. (2013) (100)
- Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study (2016) (99)
- Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. (1995) (99)
- Specific Inhibition of DNMT1 by Antisense Oligonucleotides Induces Re-expression of Estrogen Receptor a (ER) in ER-negative Human Breast Cancer Cell Lines (2003) (95)
- Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. (2004) (93)
- Comparison of Paclitaxel-, 5-Fluoro-2′-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis (1999) (92)
- A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. (2003) (92)
- Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial (2006) (92)
- Role of DNA Methylation and Histone Acetylation in Steroid Receptor Expression in Breast Cancer (2001) (91)
- Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 (2015) (91)
- Transcriptional control of glutathione S-transferase gene expression by the chemoprotective agent 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz) in rat liver. (1990) (91)
- Estrogen Receptor α Mediates Breast Cancer Cell Resistance to Paclitaxel through Inhibition of Apoptotic Cell Death (2007) (90)
- Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. (2012) (88)
- Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells (2012) (88)
- Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. (1999) (86)
- Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. (2012) (86)
- Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. (1994) (85)
- Induction of programmed cell death in human breast cancer cells by an unsymmetrically alkylated polyamine analogue. (1995) (84)
- Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. (1994) (82)
- Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer (2010) (81)
- Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
- Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. (2008) (79)
- Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2008) (79)
- Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial. (2009) (78)
- Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. (2010) (77)
- The follow-up of breast cancer. (2003) (77)
- Epigenetic Regulation as a New Target for Breast Cancer Therapy (2007) (77)
- Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. (2018) (76)
- Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. (1993) (75)
- Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. (1992) (75)
- Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. (2012) (75)
- Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. (2019) (74)
- Transcriptional control of thymidine kinase gene expression by estrogen and antiestrogens in MCF-7 human breast cancer cells. (1986) (73)
- Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. (2013) (73)
- Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer (2014) (72)
- A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells. (2003) (72)
- Molecular mechanisms of polyamine analogs in cancer cells. (2005) (72)
- Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage (2015) (71)
- Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer (2012) (71)
- Functional Interaction of Histone Deacetylase 5 (HDAC5) and Lysine-specific Demethylase 1 (LSD1) Promotes Breast Cancer Progression (2016) (71)
- A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer (2008) (71)
- Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study (2012) (71)
- E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer (2005) (71)
- Trastuzumab in breast cancer. (2004) (70)
- Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. (1995) (69)
- Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. (2007) (68)
- A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer (2014) (67)
- The search for ESR1 mutations in breast cancer (2013) (65)
- Polyamine analogue induction of programmed cell death in human lung tumor cells. (1996) (64)
- Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. (2008) (63)
- Growth inhibition of hormone-responsive and -resistant human breast cancer cells in culture by N1, N12-bis(ethyl)spermine. (1993) (63)
- Adjuvant endocrine therapy for premenopausal women with early breast cancer (2007) (63)
- Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells (2009) (63)
- C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. (2011) (63)
- Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer (2018) (62)
- Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. (2000) (61)
- Hormonal therapy in breast cancer: A model disease for the personalization of cancer care (2012) (60)
- Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells. (1996) (59)
- A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer (2012) (58)
- Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure (2016) (58)
- TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer (2015) (58)
- Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells (2014) (58)
- Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial (2005) (58)
- American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. (2011) (58)
- Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products. (1986) (58)
- Detection and Quantification of the Evolution Dynamics of Apoptosis Using the PET Voltage Sensor 18F-Fluorobenzyl Triphenyl Phosphonium (2009) (58)
- Practical Approach to Triple-Negative Breast Cancer. (2017) (56)
- The role of estrogens in growth regulation of breast cancer. (1989) (56)
- A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer (2017) (55)
- Methyl-group dietary intake and risk of breast cancer among African-American women: a case–control study by methylation status of the estrogen receptor alpha genes (2003) (55)
- Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer (2016) (54)
- Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. (2002) (54)
- Pharmacogenetics in the treatment of breast cancer (2004) (54)
- Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. (1996) (54)
- Biology of breast cancer (1991) (53)
- Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions (2012) (53)
- Primary systemic therapy in operable breast cancer. (2000) (52)
- v-rasH induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line. (1990) (51)
- Update: NCCN practice guidelines for the treatment of breast cancer. National Comprehensive Cancer Network. (1999) (50)
- The molecular landscape of premenopausal breast cancer (2015) (50)
- PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? (2007) (49)
- Estrogen Replacement Therapy in Breast Cancer Survivors-Reply (1995) (48)
- Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. (1994) (48)
- Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial (2013) (47)
- Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells (1999) (46)
- Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. (2001) (46)
- Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression (1998) (46)
- Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831 (2012) (46)
- Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies (2018) (46)
- WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines (2016) (45)
- Screening for therapeutic targets of vorinostat by SILAC‐based proteomic analysis in human breast cancer cells (2010) (44)
- CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer (2019) (44)
- Ovarian ablation as adjuvant therapy for breast cancer. (2001) (44)
- What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? (2004) (44)
- Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831 (2013) (44)
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary. (2018) (43)
- Multiparametric and Multinuclear Magnetic Resonance Imaging of Human Breast Cancer: Current Applications (2004) (43)
- Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. (2018) (43)
- Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. (2010) (42)
- Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100 (2014) (41)
- HDAC5–LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells (2018) (41)
- Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth (2017) (41)
- Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors (2014) (41)
- Ovarian ablation as adjuvant therapy for breast cancer. (2001) (40)
- Protein Phosphatase 2A Regulates Estrogen Receptor α (ER) Expression through Modulation of ER mRNA Stability* (2005) (40)
- The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines (2010) (40)
- A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. (2004) (39)
- Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials (2022) (39)
- Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198) (2015) (39)
- Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. (1990) (39)
- Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts. (1991) (39)
- Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199 (2007) (38)
- S4-6: A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194. (2011) (38)
- Regulation of Estrogen Receptor α Function in Breast Cancer (1997) (38)
- Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells (2012) (38)
- Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. (2020) (37)
- Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells. (2013) (37)
- Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China (1997) (37)
- Epigenetic regulation of protein phosphatase 2A (PP2A), Lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells (2004) (36)
- Regulation of polyamine analogue cytotoxicity by c-Jun in human MDA-MB-435 cancer cells. (2004) (36)
- Polyamine Analogues Down-regulate Estrogen Receptor α Expression in Human Breast Cancer Cells* (2006) (36)
- Integrated Proteomic and Metabolic Analysis of Breast Cancer Progression (2013) (35)
- Novel Insight into KLF4 Proteolytic Regulation in Estrogen Receptor Signaling and Breast Carcinogenesis* (2012) (34)
- A "bone" fide predictor of metastasis? Predicting breast cancer metastasis to bone. (2006) (33)
- Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative (2021) (33)
- AACR Cancer Progress Report 2016 (2016) (32)
- Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial. (2009) (32)
- Of Snail, mice, and women. (2005) (32)
- Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer. (1993) (32)
- Hormone-replacement therapy--breast versus heart versus bone. (1995) (32)
- Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. (1995) (32)
- Effects of the polyamine analogues N1-ethyl-N11-((cyclopropyl)methyl)-4,8-diazaundecane and N1-ethylN-11-((cycloheptyl)methyl)-4,8-diazaundecane in human prostate cancer cells. (2000) (32)
- Disease Subtype–Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A (2017) (31)
- Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione S-transferase in resistance. (1992) (31)
- RETRACTED ARTICLE: Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy (2013) (30)
- Gene expression profiling of breast cancer. (2008) (29)
- Adjuvant hormonal therapy for premenopausal women with breast cancer. (2003) (28)
- Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole (2011) (28)
- Sometimes a great notion--an assessment of neoadjuvant systemic therapy for breast cancer. (2005) (28)
- Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. (2013) (28)
- Inhibition of histone deacetylases. (2011) (27)
- Monoclonal antibody cocktail as an enrichment tool for acetylome analysis. (2011) (27)
- of disease Estrogen Carcinogenesis in Breast Cancer (2006) (27)
- Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer (2013) (27)
- A Pilot Phase II Trial of Valspodar Modulation of Multidrug Resistance to Paclitaxel in the Treatment of Metastatic Carcinoma of the Breast (E1195): A Trial of the Eastern Cooperative Oncology Group (2006) (26)
- Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198 (2010) (26)
- Effect of hepatocarcinogens on the binding of glucocorticoid-receptor complex in rat liver nuclei. (1976) (26)
- Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms. (2014) (26)
- The Reliability of Nipple Aspirate and Ductal Lavage in Women at Increased Risk for Breast Cancer—a Potential Tool for Breast Cancer Risk Assessment and Biomarker Evaluation (2007) (26)
- Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. (2016) (26)
- AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health (2018) (26)
- Apoptosis in the mammary gland and breast cancer (1998) (25)
- Tamoxifen--panacea or Pandora's box? (1992) (25)
- A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer (2015) (25)
- Ovarian ablation as treatment for young women with breast cancer. (1994) (25)
- Programmed cell death in human breast cancer cells. (1996) (25)
- Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer (2009) (25)
- EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial (2014) (25)
- Epigenetic reprogramming in breast cancer: From new targets to new therapies (2014) (25)
- Regulation of estrogen receptor alpha function in breast cancer. (1997) (24)
- Induction of spermidine/spermine N1-acetyltransferase in breast cancer tissues treated with the polyamine analogue N1,N11-diethylnorspermine (2004) (24)
- Adjuvant endocrine therapy for premenopausal women with breast cancer. (2009) (23)
- Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. (2013) (23)
- Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells (2006) (23)
- Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood (2018) (22)
- Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 (2013) (22)
- Environmental estrogens and breast cancer risk (1998) (22)
- Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse. (1992) (22)
- Epigenetics meets estrogen receptor: regulation of estrogen receptor by direct lysine methylation. (2009) (21)
- RETRACTED ARTICLE: Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy (2014) (21)
- Expertise vs evidence in assessment of breast biopsies: an atypical science. (2015) (21)
- Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression. (2017) (21)
- Induction of jun Gene Family Members by Transforming Growth Factor α but not 17β-Estradiol in Human Breast Cancer Cells (1993) (21)
- Aflatoxin inhibition of glucocorticoid finding capacity of rat liver nuclei. (1976) (20)
- Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells (2000) (20)
- Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer (2011) (20)
- Combined endocrine therapy for breast cancer--new life for an old idea? (2000) (20)
- The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831 (2015) (19)
- Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility. (2005) (19)
- Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. (2006) (19)
- Good news about oral contraceptives. (2002) (19)
- Breast cancer biology blossoms in the clinic (1998) (19)
- Chemoprotection by inducers of electrophile detoxication enzymes. (1993) (18)
- Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. (2016) (18)
- Developing in vitro models of human ductal carcinoma in situ from primary tissue explants (2015) (18)
- Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial. (2004) (18)
- Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer (2011) (18)
- Genotypic characterization of phenotypically defined triple-negative breast cancer. (2009) (18)
- Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update (2021) (18)
- Out of the courtroom and into the clinic. (1992) (18)
- HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. (2004) (17)
- Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of Igf1r That Persists Long after Parturition (2015) (17)
- Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs (2015) (17)
- Role of p53/p21Waf1/Cip1 in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells (2005) (17)
- Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update (2022) (16)
- Adjuvant endocrine therapy for breast cancer: how long is long enough? (2013) (16)
- Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. (2020) (16)
- Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update (2022) (16)
- Stimulation of breast cancer with estrogens: how much clinical value? (1987) (16)
- A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer. (2011) (16)
- Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts. (1996) (16)
- The silent estrogen receptor--can we make it speak? (2009) (16)
- Tobacco control: reducing cancer incidence and saving lives. American Society of Clinical Oncology. (1996) (16)
- Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation (2021) (16)
- A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC). (2011) (15)
- Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100). (2009) (15)
- Epigenetic Biomarkers and Breast Cancer: Cause for Optimism (2006) (15)
- Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. (2015) (15)
- A Phase II Study of the Polyamine Analog N 1 , N 11-Diethylnorspermine ( DENSpm ) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer (2003) (15)
- Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study. (2012) (15)
- Human Cancers Associated with Aberrant DNA Methylation in All Common Gene Is Frequently CDKN 2 / p 16 / MTS 1 Inactivation of the Updated (2006) (15)
- Apoptosis and Breast Cancer (1999) (15)
- TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer (2012) (15)
- Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer (2013) (15)
- African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. (2009) (15)
- Pesticides and breast cancer: fact or fad? (1997) (15)
- A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer (2007) (14)
- Adjuvant hormonal therapy for premenopausal women with breast cancer. (2006) (14)
- Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC) (2008) (14)
- Transferases S Role of Induction of Glutathione Ethoxyquin : Formation , and Hepatic Tumorigenesis in Rats Fed-guanine 7 N Modulation of Aflatoxin Metabolism , Aflatoxin-Updated Version (2006) (13)
- Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial. (2016) (13)
- Aromatase inhibitors for breast cancer (2007) (13)
- Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cells. (2006) (13)
- Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study. (2000) (13)
- Hematopoietic growth factors: Personalization of risks and benefits (2012) (13)
- What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer? (2009) (13)
- Protein Phosphatase 2A (PP2A) regulates Estrogen Receptor Alpha (ER) expression through modulation of ER mRNA stability. (2005) (13)
- Abstract S1-07: Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 (2013) (13)
- Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma (2020) (12)
- Dose intensity for breast cancer. (2001) (12)
- Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. (2009) (12)
- Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer (MBC): preliminary results of the Eastern Cooperative Oncology Group Trial E3198 (Abstract) (2003) (12)
- Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence (2009) (12)
- Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression (2017) (11)
- The regulation of estrogen receptor expression and function in human breast cancer. (1998) (11)
- New Strategies in Metastatic Hormone Receptor–Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies (2016) (11)
- Abstract 4666: A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) andentinostat (MS-275) in patients with triple-negative advanced breast cancer. (2013) (11)
- Chemoprevention for breast cancer: overcoming barriers to treatment. (2012) (10)
- "MAPping" the course of chemoprevention in breast cancer. (2011) (10)
- Improving Goal Concordant Care Among 10 Leading Academic U.S. Cancer Hospitals: A Collaboration of the Alliance of Dedicated Cancer Centers (2021) (10)
- Breast cancer consensus meetings: vive la difference? (2002) (10)
- Abstract S3-08: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial (2015) (10)
- Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. (2007) (10)
- Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193. (2005) (10)
- Role of p53/p21(Waf1/Cip1) in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells. (2005) (10)
- Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. (2011) (9)
- Final Results of ECOG1100: A phase I/II study of combined blockade of the ErbB receptor network in patients with HER2- overexpressing metastatic breast cancer (MBC) (2007) (9)
- Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer. (2006) (9)
- Use of SERMs for the Adjuvant Therapy of Early‐Stage Breast Cancer (2001) (9)
- Recurrent hyperactive ESR 1 fusion proteins in endocrine therapy-resistant breast cancer (2018) (9)
- Biology of breast cancer and its clinical implications (1992) (9)
- Silencing estrogen receptor alpha in breast cancer cells. (2006) (8)
- Multiparametric Magnetic Resonance Imaging, Spectroscopy and Multinuclear ( 23 Na) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer (2012) (8)
- Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. (2011) (8)
- Advances in Brief Aberrant Methylation of the Estrogen Receptor and E-Cadherin 5 * CpG Islands Increases with Malignant Progression in Human Breast Cancer 1 (2000) (8)
- Image-based risk score to predict recurrence of ER+ breast cancer in ECOG-ACRIN Cancer Research Group E2197. (2018) (8)
- 10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features. (2012) (8)
- Can Circulating Tumor Cells Predict Resistance in Metastatic Breast Cancer? (2015) (8)
- Abstract S5-4: EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial. (2012) (8)
- CT evaluation of breast cancer: spectrum of disease. (1993) (7)
- Protein kinase C and breast cancer. (1996) (7)
- Obesity and Breast Cancer: A Multipartite Connection (2013) (7)
- Combined therapy in advanced breast cancer. (1985) (7)
- The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814 (2016) (7)
- The Importance of Cytologic Intrarater and Interrater Reproducibility: the Case of Ductal Lavage (2006) (7)
- Author reply (7)
- Aromatase inhibitors as adjuvant therapy in breast cancer. (2003) (7)
- Patterns of recurrence by sequence of chemotherapy and radiotherapy in early stage breast cancer (2003) (7)
- A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer (1999) (7)
- Targeting tumorigenicity of breast cancer stem-like cells using combination epigenetic therapy: something old and something new. (2016) (7)
- Apoptosis in hormone-responsive malignancies. (1997) (7)
- OT3-01-06: A Phase 2 Study Investigating the Safety, Efficacy and Surrogate Biomarkers of Response of 5-Azacitidine (5-AZA) and Entinostat (MS-275) in Patients with Advanced Breast Cancer. (2011) (7)
- c-MYC amplification and correlation with patient outcome in early stage HER2+ breast cancer from the NCCTG adjuvant intergroup trial N9831. (2009) (7)
- Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196. (2006) (7)
- Adjuvant endocrine therapy for breast cancer: don't ditch the switch! (2011) (7)
- Biomarkers and surrogacy: relevance to chemoprevention. (2001) (7)
- Early operable breast cancer (2000) (6)
- Is hormone replacement therapy a risk? (1996) (6)
- Breast cancer: The 21-gene recurrence score — biology remains at the forefront (2016) (6)
- Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis (2022) (6)
- HER2 concordance between central laboratory immunohistochemistry and quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197 (2008) (6)
- Case records of the Massachusetts General Hospital. Case 35-2005. A 56-year-old woman with breast cancer and isolated tumor cells in a sentinel lymph node. (2005) (6)
- Abstract S3-03: Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer (2015) (6)
- Silencing estrogen receptor α in breast cancer cells (2006) (6)
- Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. (2003) (6)
- Pilot trial of paclitaxel-herceptin adjuvant therapy for early stage breast cancer (E2198) (2001) (6)
- Is it time to ReSET the standard for estrogen receptor testing in breast cancer? (2010) (6)
- Should we embrace or ablate our urge to (ovarian) suppress? (2014) (6)
- Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer (2004) (6)
- Ongoing US cooperative group trials using taxanes in the adjuvant setting. (2002) (6)
- Induction of jun gene family members by transforming growth factor alpha but not 17 beta-estradiol in human breast cancer cells. (1993) (6)
- The maturation of medical oncology. (2007) (5)
- Postoperative endocrine therapy for invasive breast cancer. (2009) (5)
- Do the ASCO/CAP 2007 HER2 Testing Guidelines Improve Prediction of Benefit to Adjuvant Trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant Trial. (2009) (5)
- Menstrual effects on surgical treatment for breast cancer. (1993) (5)
- Ki67 Assessment in Breast Cancer: Are We There yet? (2020) (5)
- Using mice to treat (wo)men: mining genetic changes in patient xenografts to attack breast cancer. (2013) (5)
- Prognostic/Predictive immunohistochemistry assays for estrogen receptor-positive breast cancer: back to the future? (2012) (5)
- Primary chemotherapy for locally advanced breast cancer using film as a novel regimen (1998) (5)
- Treatment for breast cancer: is time really of the essence? (2013) (5)
- The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831. (2013) (5)
- The American Society of Clinical Oncology Cancer Foundation Grants Program: a 25-year report and a look toward the future. (2010) (5)
- Breast cancer in 2013: Genomics, drug approval, and optimal treatment duration (2014) (5)
- Breast cancer metastatic to the choroid. (1998) (5)
- Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. (2016) (4)
- The use of anthracyclines and taxanes for adjuvant therapy of breast cancer (2001) (4)
- GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer. (2009) (4)
- Funding for clinical (patient-oriented) oncology research: current status and recommendations for improvement. American Society of Clinical Oncology. (1996) (4)
- Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome (2013) (4)
- P7 antigen expression in human breast cancer. (2003) (4)
- S35 Adjuvant therapies for premenopausal women with endocrine-responsive disease (2009) (4)
- Optimal adjuvant endocrine therapy for breast cancer. (2021) (4)
- Radiotherapy concurrent with trastuzumab is well tolerated in the adjuvant treatment of women with HER2-positive breast cancer: cardiac safety data from the NCCTG N9831 study (2006) (4)
- HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors? (2016) (4)
- Black Race Is Associated with a Worse Outcome in Patients with Hormone Receptor Positive, HER2-Normal Breast Cancer Treated with Adjuvant Chemohormonal Therapy. (2009) (4)
- Concordance of local and central laboratory hormone and HER2 receptor status in ECOG 2197 (2007) (4)
- Bernard Fisher, MD: In Memoriam (1918–2019) (2020) (4)
- Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network (2020) (4)
- Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer (2020) (3)
- HER2-targeted therapies: how far we've come--and where we're headed. (2011) (3)
- Updates in endocrine therapy for metastatic breast cancer (2021) (3)
- Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer. (2010) (3)
- Stomatitis-Related Pain in Women With Breast Cancer Undergoing Autologous Hematopoietic Stem Cell Transplant (2008) (3)
- Small beginnings: do they matter? The importance of lymphovascular invasion in early breast cancer. (2009) (3)
- Déjà vu for breast cancer two? (2004) (3)
- Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer. (2014) (3)
- 204 – Breast Cancer and Benign Breast Disorders (2012) (3)
- Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation? (2016) (3)
- P2-12-02: Correlation between BMI and Clinical Outcome of Patients with Early Stage HER2+ Breast Cancer from the N9831 Clinical Trial. (2011) (3)
- Long term follow‐up of women treated with 16‐week, dose‐intensive adjuvant chemotherapy for high risk breast carcinoma (1999) (3)
- Diseases of the Breast Jay R. Harris, Marc E. Lippman, Monica Morrow, Samuel Hellman, eds. Philadelphia: Lippincott-Raven, 1996. 1047 pp., illus. $169. ISBN 0-397-51470-0 (1997) (3)
- Increasing doses of cyclophosphamide suppress antigen-specific T helper-dependent immunity induced by a GM-CSF-secreting breast tumor vaccine (2008) (3)
- 25 Years Later: Endangered Species or Successful Evolution? (2011) (3)
- Mechanisms of Chemoprotection against Aflatoxin-Induced Hepatocarcinogenesis by Oltipraz (1991) (3)
- Follow-up Care for Cancer: Making the Benefits Equal the Cost (2000) (2)
- Adjuvant ovarian suppression in premenopausal breast cancer | NOVA. The University of Newcastle's Digital Repository (2015) (2)
- Extending Adjuvant Endocrine Therapy in Breast Cancer: Who, What, Why? (2019) (2)
- Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other Pathways. (2009) (2)
- The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility (2020) (2)
- New findings about endocrine therapy for breast cancer. (2003) (2)
- “Take two”? The role of second opinions for breast biopsy specimens (2016) (2)
- Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era. (2019) (2)
- Association of a compact 13-gene VEGF signature with OS in E2100. (2012) (2)
- Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer (2003) (2)
- Abstract P6-13-01: Local excision without radiation for ductal carcinoma in situ: 12-year results from the ECOG E5194 study (2015) (2)
- A Phase I Toxicity and Feasibility Trial of Sequential Dose-Dense Induction Chemotherapy with Doxorubicin, Paclitaxel, and 5-Fluorouracil Followed by High Dose Consolidation for High-Risk Primary Breast Cancer (2002) (2)
- Fifteen years of anti-HER2 therapy. (2013) (2)
- Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2+BC): Results from the NCCTG adjuvant Intergroup trial N9831 (2008) (2)
- How we maintain bone health in early-stage breast cancer patients on aromatase inhibitors. (2007) (2)
- A pilot study evaluating surrogates of response to short-term vorinostat in women with newly diagnosed breast cancer. (2009) (2)
- Management of Early Stage Breast Cancer (1997) (2)
- A phase I study of diethylnorspermine (DENSPM) in previously treated patients with metastatic breast cancer (MBC) (2001) (2)
- Screening for therapeutic targets of vorinostat by SILAC‐based proteomic analysis in human breast cancer cells (2010) (2)
- What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer? (2009) (2)
- Incident Cancer in Cancer Survivors-When Cancer Lurks in the Background. (2017) (1)
- Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma (2019) (1)
- Selection of Adjuvant Endocrine Therapy for Women with Breast Cancer in Menopausal Transition: Is It Simpler than We Thought? (2021) (1)
- Optimal duration of trastuzumab for early HER2-positive breast cancer (2017) (1)
- A prospective study of adjuvant anastrozole and gene promoter methylation in the contralateral breast of high-risk women (2008) (1)
- Mitotic index to predict breast cancer recurrence after neoadjuvant systemic therapy. (2016) (1)
- Conquering Metastatic Breast Cancer. (2016) (1)
- Cancer Care at the Beginning of the COVID-19 Pandemic (2022) (1)
- S28 Ovarian function suppression in the adjuvant program (2007) (1)
- Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer (2010) (1)
- Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER+ or to ER- disease? (2016) (1)
- Protein Phosphatase 2A (PP2A) regulates estrogen receptor alpha (ER) expression through interaction with the ER promoter. (2004) (1)
- Abstract P5-06-16: Histomorphometric measure of disorder of collagen fiber orientation is associated with risk of recurrence in ER+ breast cancers in ECOG-ACRIN E2197 and TCGA-BRCA (2020) (1)
- 116 Inhibition of p53-MDM2 pathway by novel boronic-chalcones (2004) (1)
- Estrogen Receptor Status, Cell Cycling and Paclitaxel: Looking for a “Hormone”-ious Explanation (2004) (1)
- Dose intensity for breast cancer: where do we go from here? (2001) (1)
- Erratum: Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer (Journal of Biological Chemistry (2005) 280 (18302-18310)) (2005) (1)
- Abstract 4877: Polyamine analogues modulate gene expression by inhibiting KDM1/LSD1 and altering chromatin structure in human breast cancer cells (2010) (1)
- Therapeutic and Chemopreventive Actions of a Novel Polyamine Analog Against Breast Cancer (2002) (1)
- Adjuvant chemotherapy of axillary lymph-node-positive breast cancer. (1992) (1)
- P2-12-13: Topoisomerase 2 alpha (TOP2A) RNA Expression Provides Prognostic Information in Hormone Receptor Positive Breast Cancer That Is Complementary to a Simulated Algorithm for Recurrence Score. (2011) (1)
- Relationship between taxane-induced neuropathy and clinical outcomes after adjuvant chemotherapy. (2011) (1)
- Gonadotropin-Releasing Hormone (GnRH) Agonists for Fertility Preservation: Is POEMS the Final Verse? (2018) (1)
- Abstract PD7-03: Investigating cortactin as a genetic driver of disease progression in invasive lobular carcinoma (2019) (1)
- Adjuvant therapy of breast cancer (2004) (1)
- PD05-03: Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831. (2011) (1)
- negative Breast Cancer Cells α in Human ER-by DNA Methyltransferase and Histone Deacetylase Inhibition α Synergistic Activation of Functional Estrogen Receptor ( ER )-Updated Version (2001) (1)
- Predictive utility of progesterone receptor (PR) and multigene expression in identifying benefit from adjuvant doxorubicin plus cyclophosphamide (AC) or docetaxel (AT) in intergroup trial E2197 (2008) (1)
- Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation (2021) (1)
- Abstract P2-11-10: Intra-tumor heterogeneity affects multi-gene test prognostic risk stratification (2013) (1)
- Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT (2022) (1)
- Abstract P3-11-10: Response to subsequent therapies after failure to achieve pathologic complete response (pCR) after neo-adjuvant chemotherapy (NAC) in patients (pts) with triple negative breast cancer (TNBC) (2015) (1)
- Abstract PD7-02: Novel human cell line xenograft models of ERα-positive metastatic invasive lobular breast carcinoma as pre-clinical platforms for validating candidate genetic drivers (2019) (1)
- EDITORIAL DéjaVu for Breast Cancer Two (2004) (1)
- Waging war on cancer Siddhartha Mukherjee The Emperor of All Maladies: A Biography of Cancer 2010 Simon & Schuster 1439107955 Pp 592. US$30·00. Watch a video of Siddhartha Mukherjee talking about this book at http://authors.simonandschuster.com/Siddhartha-Mukherje (2011) (1)
- Adjuvant endocrine therapy: controversies and perspectives (2006) (1)
- 91 – Cancer of the Breast (2014) (1)
- Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer? (2017) (1)
- Abstract P5-07-01: Successful whole transcriptome analysis of 25-year-old breast tumor samples from the phase III trial SWOG-8814 by next generation sequencing (NGS): Standardized analytical methods for exploratory and validation studies (2016) (1)
- Stage migration and micrometastases (2002) (1)
- Abstract 1052: Synergy between inhibition of novel histone demethylase (LSD2) and DNA methyltransferase (DNMT) and histone deacetylase (HDAC) in modulating gene expression and inhibiting growth in human breast cancer cells (2012) (1)
- Abstract 1385: New insights into the roles of histone lysine-specific demethylase 2 (LSD2) in breast cancer (2017) (1)
- The Molecular Biology of Breast Cancer (2015) (1)
- Estrogen Replacement Therapy in Breast Cancer Survivors (1995) (1)
- Comprehensive 2D and 3D phenotypic characterization of human invasive lobular carcinoma cell lines (2018) (1)
- Adjuvant chemo endocrine therapy (2014) (1)
- Advances in Adjuvant and Neoadjuvant Therapy for Breast Cancer (2011) (1)
- A digital health intervention to improve nutrition and physical activity in breast cancer survivors: Rationale and design of the Cook and Move for Your Life pilot and feasibility randomized controlled trial. (2022) (1)
- Abstract P3-05-14: A neoadjuvant window trial of endocrine response in women with invasive lobular carcinoma (2016) (1)
- Abstract P6-05-10: An international survey on invasive lobular breast cancer (ILC) reveals gaps in knowledge and top priority research areas (2023) (0)
- Utilization of Magee equation 3 in ER-positive, HER2-negative/equivocal tumors to determine pathologic response to neoadjuvant therapy. (2016) (0)
- A Phase II Study of the Polyamine Analog N,N- Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer (2003) (0)
- Abstract 6231: Predictors of objectively-measured sedentary time during the COVID-19 pandemic among breast cancer survivors participating in a diet and physical activity intervention (2022) (0)
- An Interview With AACR’s President-Elect (2015) (0)
- Pathologic complete response (pCR) to preoperative sequential doxorubicin/cyclophosphamide (AC) and taxane (AC-T) or AC followed by paclitaxel and trastuzumab (AC-TH) in stage II-III HER2-positive breast cancer (2008) (0)
- Phase I II, M ulticenter, D ouble-Blind, R andomized S tudy of L etrozole, a n A romatase I nhibitor, f or A dvanced B reast Cancer V ersus M egestrol A cetate (2001) (0)
- Tracking 35 years of progress against breast cancer. (2008) (0)
- Cost Burden Analysis of Ineffective Induction Chemotherapy in Elderly Patients with AML. (2009) (0)
- Abstract P1-06-08: Independent validation of EarlyR gene signature in E2197: A randomized clinical trial comparing doxorubicin plus docetaxel to doxorubicin plus cyclophosphamide as adjuvant chemotherapy in breast cancer (2018) (0)
- The challenges in translating present knowledge of the molecular biology of breast cancer into clinical use (2005) (0)
- Abstract P2-09-08: c-MYC (MYC) Protein Expression and Associations with Trastuzumab Benefit in Early-Stage, HER2+ Breast Cancer in Context of the NCCTG Adjuvant Trial, N9831 (2010) (0)
- Abstract 5700: Establishing candidate biomarkers for the pharmacodynamic action of sulforaphane in the breast (2010) (0)
- Biology of breast cancer and its clinical implications. (1992) (0)
- Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer (2011) (0)
- Exploring Current Tests, Treatments in Breast Cancer Management (2018) (0)
- Abstract CT509: Cook and Move for Your Life: A pilot study of an online intervention to improve diet and physical activity among breast cancer survivors (2022) (0)
- Abstract P1-08-35: Stromal tumor infiltrating lymphocytes analysis by race and ethnicity in triple negative breast cancers from 2 phase III randomized adjuvant breast cancer trials: ECOG-ACRIN E2197 and E1199 (2022) (0)
- Antigen Expression in Human Breast Cancer 1 (2003) (0)
- Abstract 3648: Proteomic profiling of vorinostat in breast cancer (2010) (0)
- The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831 (2015) (0)
- Skeletal Complications of Malignancy Supplement to Cancer The Biology of Breast Carcinoma (2003) (0)
- ESTROGEN REPLACEMENT THERAPY IN BREAST CANCER SURVIVORS. AUTHORS' REPLY (1995) (0)
- Abstract 673: Targeting LSD1-HDACs crosstalk as a potential therapeutic strategy for triple negative breast cancer cells. (2013) (0)
- Oral 1831-2 – Therapeutic actions of electrophilic nitroalkenes via inhibition of the NFκB pathway in triple negative breast cancer (2014) (0)
- Gender differences in faculty rank and subspecialty choice in academic medical oncology. (2020) (0)
- Handbook of Women's Health: Breast cancer screening (2001) (0)
- Detection and functional analysis of estrogen receptor mutations (ESR1-mut) in patients with metastatic breast cancer (MBC). (2015) (0)
- Abstract 5645: Associations between biomarkers and outcome in a patient cohort with invasive lobular carcinoma (2017) (0)
- Carcinogen effects of glucocorticoid nuclear binding in rat liver (1976) (0)
- Abstract A47: Establishing candidate biomarkers for the pharmacodynamic action of sulforaphane in the breast (2010) (0)
- Advances in Brief Demethylation of the Estrogen Receptor Gene in Estrogen Receptor-negative Breast Cancer Cells Can Reactivate Estrogen Receptor Gene Expression 1 (1995) (0)
- Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood (2018) (0)
- Advances in Brief Induction of Programmed Cell Death in Human Breast Cancer Cells by an Unsymmetrically Alkylated Polyamine Analogue 1 (2006) (0)
- Methylation-specific Polymerase Chain Reaction Mapping of ER Gene CpG Island Methylation by Updated (2006) (0)
- ER Recruits Distinctive Corepressor Complexes Negative Breast Cancer Cells : Tamoxifen-Bound Reactivated − Restoration of Tamoxifen Sensitivity in Estrogen Receptor (2006) (0)
- 767 poster PARTIAL BREAST IRRADIATION WITH CONCURRENT DOSE DENSE DOXORUBICIN & CYCLOPHOSPHAMIDE: LATE TOXICITY & RECURRENCE (2011) (0)
- Restrospective on the last quarter-century in medical oncology. (2011) (0)
- Abstract P6-05-03: Exogenous steroid hormone exposure and the biology of lobular breast cancer (2020) (0)
- Challenges and opportunities for physician-scientists in advancing cancer research. (2022) (0)
- Reply to J.M. Guinebretiere and L. Arnould et al (2009) (0)
- EDITORIALS Pesticides and Breast Cancer: Fact or Fad? (1997) (0)
- Abstract GS2-03: Highly recurrent transcriptional remodeling events in advanced endocrine resistant ER-positive breast cancers (2018) (0)
- Reply to C. Shah et al. (2016) (0)
- Breast Cancer (2018) (0)
- Abstract B104: Targeting Nrf2/ARE pathway by inhibition of HDAC in breast cancer prevention (2008) (0)
- In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer. (2022) (0)
- Abstract 3838: Functional crosstalk between histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) as a novel therapeutic target in triple-negative breast cancer cells (2015) (0)
- Abstract A1-07: Identification of base pair mutations and structural rearrangements acquired in breast cancer metastases including a novel hyperactive ESR1-DAB2 fusion gene in hormone-resistant progression (2015) (0)
- Abstract 1044: Breast cancer subtype-specific regulation of gene transcription and therapeutic response by functional crosstalk between LSD1 and HDACs (2012) (0)
- WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines (2016) (0)
- Estrogenic regulation of polyamine analogue cytotoxicity in human breast cancer cells (2005) (0)
- Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. (2023) (0)
- Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists (2020) (0)
- PG 11.01 Endocrine therapy for premenopausal women: type and duration (2015) (0)
- NATIONAL INSTITUTES OF HEALTH National Cancer Institute Clinical Trials and Translational Research Advisory Committee CHAIR (2016) (0)
- Human Breast Cancer following Estrogen Ablation Programmed Cell Death during Regression of the MCF-7 Updated Version (2006) (0)
- The Schwartz/Billingsley/Wallner article reviewed (2000) (0)
- APhase I-II Study of Combined Blockade of the ErbBReceptor Network with Trastuzumab and Gefitinib in Patients with HER 2 ( ErbB 2 )-OverexpressingMetastatic Breast Cancer (2008) (0)
- Electrophilic Nitroalkenes Cause Degradation of NFκB RelA Protein in Triple Negative Breast Cancer Cells (2015) (0)
- Electrophilic Nitroalkenes Inhibit Triple Negative Breast Cancer Metastasis (2016) (0)
- PerspectivesofPostmenopausalBreastCancer SurvivorsonAdjuvantEndocrineTherapy-Related Symptoms (2014) (0)
- Abstract S4-04: Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR) positive, HER2-negative early stage breast cancer (ESBC) (2017) (0)
- Commentary (Wolff/Davidson): Twenty Years of Systemic Therapy for Breast Cancer (2006) (0)
- Abstract P2-03-17: Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2+ or HER2- metastatic breast cancer (2023) (0)
- Advances in Brief Inhibition of Fatty Acid Synthesis Induces Programmed Cell Death in Human Breast Cancer Cells 1 (2006) (0)
- Biology and prognostic factors of breast cancer. (1990) (0)
- ANTIOXIDANTS AND ONCOGENESIS: ROLES IN CANCER CAUSATION AND PREVENTION (1993) (0)
- Adjuvant Endocrine Therapy Trials in Premenopausal Patients (2003) (0)
- Abstract PD7-07: Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer – new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814 (2017) (0)
- Histone deacetylase inhibition reactivates the silenced estrogen receptor alpha gene and sensitizes ER-negative human breast cancer cells to Tamoxifen (2006) (0)
- Searching for the IDEAL Duration of Adjuvant Endocrine Therapy. (2018) (0)
- The molecular landscape of premenopausal breast cancer (2015) (0)
- Abstract P6-08-02: Developing in vitro models of ductal carcinoma in situ from primary tissue (2016) (0)
- Metastatic Breast Cancer: Tailored Endocrine Therapy for Premenopausal Women (2006) (0)
- Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB 7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer (2011) (0)
- A Digital Health Intervention to Improve Nutrition and Physical Activity in Breast Cancer Survivors: Rationale and Design of the Cook and Move for Your Life Pilot Randomized Controlled Trial (2022) (0)
- Martin D. Abeloff, MD. (2008) (0)
- New data on endocrine treatments (2003) (0)
- Session 11: Adjuvant systemic treatment for the individual patient I: Endocrine therapies: New aspects for old treatments (2015) (0)
- Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models (2017) (0)
- New data on adjuvant therapy for breast cancer (1999) (0)
- The Mina/Sledge article reviewed (2006) (0)
- Inhibition of Fatty Acid Synthesis Induces Programmed Cell Death in Human Breast Cancer Cells 1 (2006) (0)
- Breast Cancer (2018) (0)
- Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells (2011) (0)
- Abstract P6-09-14: Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer (2017) (0)
- Predictive Biomarkers and Personalized Medicine Impact of c-MYC Protein Expression on Outcome of Patients withEarly-StageHER 2 þ BreastCancerTreatedwithAdjuvant Trastuzumab NCCTG ( Alliance ) N 9831 (2013) (0)
- Abstract 2841: Investigating drivers of disease progression in invasive lobular carcinoma (2017) (0)
- Search worldwide , lifesciences literature (2012) (0)
- Targeting a future without cancer Sincerely (2009) (0)
- Reply to N. Magné et al (2009) (0)
- Paradigm Shift in Adjuvant Treatment of Receptor Positive Premenopausal Breast Cancer Patients ? Not Yet ! (2003) (0)
- Platelet Activation and Atherothrombosis (2008) (0)
- Locoregional F ailure 1 0 Y ears A fter M astectomy and A djuvant C hemotherapy W ith o r W ithout T amoxifen Without I rradiation: E xperience o f t he E astern Cooperative O ncology G roup (1999) (0)
- t reatment f or Breast Cancer: is t ime r eall y of the Essence? (2012) (0)
- 750 poster COSMETIC OUTCOME AFTER PARTIAL BREAST IRRADIATION WITH CONCURRENT CHEMOTHERAPY IN EARLY-STAGE BREAST CANCER (2011) (0)
- Abstract 1993: Interaction between histone demethylase and deacetylase may mediate activity of HDAC inhibitors in human breast cancer cells (2011) (0)
- A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer (2017) (0)
- Abstract S1-03: Identification of base pair mutations and structural rearrangements acquired in breast cancer metastases including a novel hyperactive ESR1-DAB2 fusion gene specifically in hormone-resistant recurrence (2015) (0)
- Breast cancer screening (2009) (0)
- BOOKS: ‘The Death of Cancer’—by Vincent T. DeVita and Elizabeth DeVita-Raeburn (2016) (0)
- Estrogens regulate production of specific growth factors in hormone-dependent human breast cancer. (1987) (0)
- Abstract 5270: Disease subtype independent biomarkers of breast cancer prevention by withaferin a (2017) (0)
- Effects of the Polyamine AnaloguesN-Ethyl-N-((cyclopropyl)methyl)- 4,8-diazaundecane andN-Ethyl-N-((cycloheptyl)methyl)-4,8- diazaundecane in Human Prostate Cancer Cells (2000) (0)
- Molecular Biology of Breast Cancer Initiation and Progression Normal Breast Development (0)
- Abstract 421: Comprehensive genomic analysis of metastatic breast cancers revealsESR1fusions as a recurrent mechanism of endocrine therapy resistance (2017) (0)
- Programmed Cell Death in an Estrogen-independent Human Breast Cancer Cell Line , MDA-MB-4681 (2006) (0)
- Breast Cancer Cells by Histone Deacetylase Inhibition in Human α Transcriptional Activation of Estrogen Receptor Updated (2000) (0)
- Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study (2020) (0)
- Cancer Metastasis: Introduction to Clinical Research (2011) (0)
- Abstract PD1-05: Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquiredERBB2amplifications and activating mutations (2017) (0)
- Targeting Histone Abnormality in Triple-Negative Breast Cancer (2015) (0)
- MultiparametricMagnetic Resonance Imaging , Spectroscopy and Multinuclear ( 23 Na ) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer (2010) (0)
- TITLE: Antineoplastic Efficacy of Novel Polyamine Analogues in Human Breast Cancer. PRINCIPAL INVESTIGATOR: (2006) (0)
- Breast Cancer Primary Prevention: ‘SERM-Mounting’ Existing Obstacles and Future Directions (2012) (0)
- Abstract S3-02: Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – Transcriptome expression analysis of the phase III trial SWOG-8814 (2016) (0)
- Growth Inhibition of Hormone-responsive and -resistant Human Breast Cancer Cells in Culture by /V1,A^-BisiethyOspermine1 (2006) (0)
- Investigating genetic drivers of disease progression in invasive lobular carcinoma (2018) (0)
- Aflatoxin effects on glucocorticoid nuclear binding in rat liver (1975) (0)
- Programmed Cell Death during Regression of the MCF-7 Human Breast Cancer following Estrogen Ablation 1 (2006) (0)
- Electrophilic Nitro‐oleic Acid Inhibits Triple Negative Breast Cancer Cell Migration via Suppression of NF‐kB activity (2017) (0)
- Abstract 3679: Modulation of estrogen depurinating DNA adduct by sulforaphane or KEAP1 knockdown in human breast epithelial cells. (2013) (0)
- Evidence-Based AET in Women Before and After Menopause (2014) (0)
- Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer (2020) (0)
- Circling Back: Duration of Adjuvant Endocrine Therapy for Breast Cancer (2014) (0)
- Selective Inhibition of Triple Negative Breast Cancer Cell Mobility and Viability by Nitro-Oleic Acid (2017) (0)
- Endocrine-Related Cancer ( 2001 ) 8 115 – 127 DNA methylation in breast cancer (2001) (0)
- Biology of breast cancer. (1991) (0)
- The Changing Landscape of Targeted Breast Cancer Therapies (2020) (0)
- Abstract 16746: Cardiovascular Disease Outcomes After Breast Cancer in Postmenopausal Women: Results From the Women’s Health Initiative (2015) (0)
- The EstrogenReceptorCpG Island Is Methylatedin Most HematopoieticNeoplasms1 (1996) (0)
- Metastatic breast cancer: a patient friendly approach with a new drug therapy (2001) (0)
- Impact of Adjuvant Trastuzumab on Locoregional Failure Rates in the NCCTG N9831 (Alliance) Study (2019) (0)
- Serendipity and purpose. (2016) (0)
- Nancy Davidson, MD, Discusses Advancements in Breast Cancer (2019) (0)
- Managing SCC of the Kidney (2019) (0)
- Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001. (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Nancy E. Davidson?
Nancy E. Davidson is affiliated with the following schools: